You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 Patient characteristics and bivariate analysis of the costs of the first 12 months after allogeneic stem cell transplantation

From: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Variable Characteristics Cost after 12 months (€)
N Mean (SD) P-value
Age (years) < 30 31 103,146 (44,270) 0.6285a
30 to 50 65 107,689 (35,434)
> 50 112 102,125 (36,422)
Sex F 87 99,375 (33,651) 0.1282b
M 121 107,353 (39,485)
Underlying disease Acute leukemia and myelodysplastic syndrome 143 100,960 (31,157) 0.2259a
Lymphoproliferative disorder 46 111,367 (48,575)
Myeloproliferative disorder 12 116,491 (56,018)
Other 7 96,756 (22,709)
Donor type HLA identical sibling 83 103,795 (41,940) 0.8294a
Unrelated donor 107 104,998 (33,467)
Cord blood unit 18 99,200 (37,742)
D/R match HLA identical sibling 83 103,795 (41,940) 0.8986a
Unrelated donor 10/10 and cord blood unit 6/6 63 102,644 (32,594)
Unrelated donor 9/10 and cord blood unit 4/6 or 5/6 62 105,706 (35,598)
Stem cell source Bone marrow 50 99,679 (39,183) 0.7950a
Peripheral blood stem cell 140 106,184 (36,604)
Cord blood unit 18 99,200 (37,742)
Conditioning regimen Reduced intensity 92 108,178 (31,779) 0.3566a
Mini 61 101,129 (42,830)
Myeloablative 55 100,256 (39,172)
Recipient CMV serology R+ 130 103,494 (34,279) 0.7950b
R- 78 104,886 (42,030)
Number of CMV episodes 0 138 99,793 (39,654) 0.0214a
1 44 104,815 (24,271)
≥2 26 125,080 (36,290)
Acute graft-versus-host disease 0 and 1 112 96,278 (37,441) 0.0011a
2 to 4 96 113,043 (35,180)
Chronic graft-versus-host disease No 140 101,858 (33,633) 0.2320b
Yes 68 108,458 (43,789)
Alive at the end of the mentioned period No 80 109,067 (29,356) 0.1227b
Yes 128 100,859 (41,270)
First CMV infection ≤100 days 53 109,015 (30,231) 0.1841 b
>100 days 18 119,834 (32,142)
  1. aAnova test; b Student test